HIV Infections
Pipeline by Development Stage
Drug Modality Breakdown
Infectious Diseases is an $11.9B market dominated by HIV and hepatitis C treatments in their peak revenue phases, reflecting a mature but stable therapeutic area.
Key Trends
- HIV antiretroviral dominance: Nucleoside Reverse Transcriptase Inhibitors account for 44% of spending
- Patent cliff pressure: $2.8B in revenue from major products facing LOE between 2027–2031
- High trial velocity: 9,337 active trials indicate sustained pipeline development despite market maturity
Career Verdict
Infectious Diseases offers stable, well-compensated roles with strong commercial demand, but limited growth upside—ideal for risk-averse professionals seeking established franchises rather than high-growth opportunities.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | BIKTARVY (bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate) | Gilead Sciences | $3.2B | 27% | Peak | Stable | 10.5yr |
| 2 | EPCLUSA (velpatasvir and sofosbuvir) | Gilead Sciences | $877M | 7% | Peak | Stable | 8.2yr |
| 3 | TIVICAY (dolutegravir sodium) | GSK | $657M | 6% | Peak | Declining | 4.1yr |
| 4 | TRIUMEQ (abacavir sulfate, dolutegravir sodium, lamivudine) | GSK | $632M | 5% | Peak | Declining | 4.1yr |
| 5 | GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) | Gilead Sciences | $626M | 5% | Peak | Stable | 6.9yr |
Drug Class Breakdown
backbone of HIV treatment, stable demand
hepatitis C treatment, mature market
boosting agents in combination regimens
niche mechanism, limited growth
Career Outlook
StableInfectious Diseases offers predictable career progression and above-average compensation in Commercial roles, supported by 780 current openings and sustained demand from market incumbents. However, patent cliffs affecting $2.8B in near-term revenue (2027–2031) will compress margins and slow hiring after 2028, particularly in Commercial support and field-based roles. The area is best suited for mid-career professionals seeking stability over rapid growth, with limited appeal for early-career scientists pursuing innovation-driven research.
Breaking In
Enter via Commercial or Manufacturing roles at GSK, Sanofi, or Becton Dickinson to build market expertise and commanding salaries ($160K–$237K); avoid pure R&D tracks unless you target specific mechanisms like long-acting injectables.
For Experienced Professionals
Experienced professionals should pursue Market Access, Medical Affairs, or Commercial Leadership roles where patent cliff expertise commands premium compensation; consider consulting or biotech transition if R&D innovation is your priority.
In-Demand Skills
Best For
Hiring Landscape
Infectious Diseases hiring is heavily weighted toward Commercial roles (247 positions, 32% of total), reflecting mature market dynamics focused on market access and brand management. GSK and Becton Dickinson lead hiring (214 and 188 roles), but Gilead Sciences—the market leader by revenue—shows surprisingly low hiring (25 roles), signaling efficiency-driven operations. Salary progression favors Commercial ($275K avg) over R&D ($184K avg), indicating career acceleration through sales and marketing functions.
Top Hiring Companies
By Department
Strong Commercial hiring with premium salaries suggests Infectious Diseases is an excellent landing spot for brand, sales, and market access professionals, but limited R&D hiring indicates reduced innovation investment.
On Market (15)
Approved therapies currently available
Competitive Landscape
82 companies ranked by most advanced pipeline stage
+52 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 45 trials with date data
Clinical Trials (50)
Total enrollment: 8,495 patients across 50 trials
Testosterone for HIV-Positive Men With Reduced Serum Testosterone Levels and Abdominal Fat
Safety and Effectiveness of Adding Saquinavir (FORTOVASE) in Soft Gel Capsule Form to an Anti-HIV Drug Combination in HIV-Infected Patients
Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia
The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection
The Safety and Effectiveness of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs
The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients
Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP
Got Doxy- 'Flipping the Script' on STI PEP
Accelerated ART Initiation for PWHIV Who Are Out of Care
Virtual PrEP: Rendering PrEP Delivery More Efficient
A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories
A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States
Sulforaphane Use to Effect Inflammatory and Metabolic Changes in Virally Suppressed HIV Patients
Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)
Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa
Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide
Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant
Study of Bictegravir/Emtricitavine/Tenofovir Alafenamide in HIV-1 Infected naïve Patients Using Test and Treat Stategy Rapid-initiation Model of Care: BIC-NOW Clinical Trial (BIC-NOW)
Doxycycline PEP for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV PrEP
Neuropsyquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study
Raltegravir One Thousand Two Hundred vs Darunavir-cb in Immnunosupressed Patients: ROTDIP Study
A Clinical Trial to Evaluate the Immunogenicity of the Nonavalent Vaccine Against Human Papillomavirus in Men Infected by HIV Who Have Sex With Men. GESIDA 10017
A Clinical Trial to Evaluate the Efficacy and Safety of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide as a First-line Treatment in Naïve Patients With HIV-1 Infection With Severe Immunosuppression
Dolutegravir and Darunavir Evaluation in Adults Failing Therapy
ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence
Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part B
Switching From Tenofovir Disoproxil Fumarate to Abacavir or Tenofovir Alafenamide
Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women
Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5
Early Antiretroviral Therapy and Pre-exposure Prophylaxis for HIV Prevention Among Female Sex Workers in Cotonou, Benin
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis
HBsAg Related Response Guided Therapy
Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus
Steroid Treatment for Hypereosinophilic Syndrome
Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV
Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients
REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial
Cryptococcal Optimal ART Timing Trial
Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients
A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells
Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)
Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV
A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects
Pilot Assessment of Lopinavir/Ritonavir and Maraviroc
Related Jobs in Infectious Diseases
Vice President, Engineering
Vice President, Engineering
Vice President, Engineering
Vice President, Engineering
Director, Anti-infective Pharmacology
Executive Search Recruiting Coordinator
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.